PLX Company Profile and Key Details

Q: Who are the executives of PLX?

Ms. Yael FellousVice President of HRMr. Yaron NaosSenior Vice President of OperationsMr. Dror BashanPres, Chief Executive Officer & DirectorMr. Eyal Rubin M.B.A.Senior Vice President, Chief Financial Officer, Treasurer & Corporation Sec.

AMEX : PLX

Protalix BioTherapeutics

$2.31

-0.06999993-2.95%

Open: 1:40 PM

62.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Protalix BioTherapeutics, Inc. (PLX) stock declined over -2.95%, trading at $2.31 on AMEX, down from the previous close of $2.38. The stock opened at $2.39, fluctuating between $2.28 and $2.39 in the recent session.

Stock Snapshot

2.375

Prev. Close

185.72M

Market Cap

2.28

Day Low

-28.81

P/E Ratio

-0.08

EPS (TTM)

-0.03

Cash Flow per Share

2.39

Open

80.57M

Number of Shares

2.385

Day High

95.35%

Free Float in %

0.46

Book Value

493.3K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	2.32	2.38	2.31	2.36	735.48K
Apr 13, 2026	2.31	2.33	2.29	2.29	418.62K
Apr 10, 2026	2.29	2.32	2.26	2.30	394.16K
Apr 09, 2026	2.25	2.30	2.19	2.28	936.48K
Apr 08, 2026	2.25	2.30	2.21	2.25	867.39K
Apr 07, 2026	2.19	2.22	2.14	2.19	451.76K
Apr 06, 2026	2.15	2.23	2.13	2.21	651.37K
Apr 02, 2026	2.15	2.16	2.07	2.15	1.1M
Apr 01, 2026	2.21	2.26	2.17	2.19	863.78K
Mar 31, 2026	2.10	2.20	2.10	2.19	961.93K
Mar 30, 2026	2.11	2.12	2.04	2.09	1.07M
Mar 27, 2026	2.10	2.21	2.09	2.14	749.25K
Mar 25, 2026	2.08	2.18	2.08	2.16	1.1M
Mar 24, 2026	2.13	2.14	2.03	2.07	728.01K
Mar 23, 2026	2.14	2.20	2.12	2.13	958.08K
Mar 20, 2026	2.21	2.24	2.11	2.14	1.54M
Mar 19, 2026	2.22	2.25	2.12	2.23	1.33M
Mar 18, 2026	2.28	2.32	2.07	2.21	3.34M
Mar 17, 2026	2.85	2.88	2.79	2.79	703.99K
Mar 16, 2026	2.77	2.92	2.77	2.87	964.63K

Contact Details

Hackensack, NJ 07601

United States

https://www.protalix.com 201 696 9345

About Company

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Funda��o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Stock Peers

TBXU

0.7952+2.49%

Direxion Daily Biotech Top 5 Bull 2X ETF$32.75 PTHS

Pelthos Therapeutics Inc.$23.00 PTN

1.98+10.70%

Palatin Technologies, Inc.$20.49 ARMP

1.19+10.18%

Armata Pharmaceuticals, Inc.$12.88 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.19+2.72%

NeurAxis, Inc.$7.18 CVM

0.34+8.46%

CEL-SCI Corporation$4.36 CANF

0.13+4.45%

Can-Fite BioPharma Ltd.$3.05 NSRX

-0.08-3.43%

Nasus Pharma Ltd.$2.25

Company Overview

Protalix BioTherapeutics, Inc. (AMEX:PLX) closed at $2.31 USD, losing -$0.07 (-2.95%) from the previous close of $2.38. The stock is currently mid-range between its 52-week high and low $1.32 and $3.19. With a market capitalization of about $185.72 million, Protalix BioTherapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.09). Key stats such as the average daily volume over the past year has been around 1.26 million shares, volume is running light vs its 52-week average. Headquartered in Hackensack, NJ, Protalix BioTherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dror Bashan, the company employs approximately 213 people and listed since May 15, 1998. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 5.54%, SMA50 31.68%, SMA200 58.07%). The stock’s 14-day RSI is 64.77 (firm momentum), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.64% below its high and over 128.03% above its low. Average 10-day trading volume of 636.47 thousand shares is below the 3-month average of 1.25 million, indicating normal recent market interest.

Valuation Metrics

Protalix BioTherapeutics, Inc. trades at a P/E ratio of -28.01, slightly below the S&P 500 average, with a price-to-sales ratio of 3.6 and a price-to-book ratio of 3.84 trading at moderately above to book value. The P/FCF stands at -15.82, also below market averages.

Dividend & Fair Value

Protalix BioTherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.49. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of $0.03. The next quarter is forecast at $0.04. Next year's EPS is expected at $38.10. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $12.00. The high target offers 408.47% upside. The low target suggests 408.47% downside. The mean target is $12.00. This offers 408.47% upside. Protalix BioTherapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -51.43%. The prior quarter beat by -93.27%. Over the last six quarters, Apple has recorded several small beats. These include 250.06% in August 14, 2024.

Shareholding & Insider Activity

Protalix BioTherapeutics, Inc. has 79.73 million shares outstanding. The public float is 60.76 million shares, elevated short interest at 4.76% of float. This equals 3.63 million shares. The short ratio is 5.82 days. Institutional investors hold 16.93% of the float. Insiders own 10.54%. Camber Capital Management LLC holds 10.78 million shares, Bronfeld Zeev has 10.07 million shares and Bio-Cell Ltd has 10.07 million shares. Over the past six months, insider transactions show balanced activity. They sold 168.00 shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Protalix BioTherapeutics generated $65.49M in revenue, or $0.79 per share. Gross margin was 64.91%, operating margin 15.97%, and net profit margin 12.69%. Returns are healthy, with ROA at 9.84% and ROE at 24.76%.
On valuation metrics, Protalix BioTherapeutics trades at a P/E of -28.01, P/S of 3.60 and P/B of 3.84. The current ratio is 2.51 and quick ratio is 1.54. Operationally, the company’s inventory turnover is 1.05 and cash conversion cycle is 337.97 days. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of -1.44.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Protalix BioTherapeutics posted revenue of $65.49M, down slightly from $47.64M in the prior quarter. Gross profit was $42.51M (margin 64.91%). Operating income was $10.46M (margin 16.0%). Net income was$8.31M (EPS $0.12).
The company ended the quarter with $44.56M in cash and short-term investments, a total debt of $26.28M, and net debt of $2.65M. Total assets were $84.43M, with equity of $33.57M. Financials further reflected weakness, with operating cash flow of - $1.32M, free cash flow of - $2.47M, and capital expenditures of - $1.15M.

Price Forecast & Outlook

Our AI price prediction model suggests that Protalix BioTherapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.25%, with price expected at $2.00 by April 28, 2026, within a range of $1.78 to $2.23 3-Month Outlook: Projected fall of -61.86%, reaching $0.90 by July 13, 2026, with a range of $0.67 to $0.99. 1-Year Outlook: Projected gain of 824.58%, with price at $21.82 by April 14, 2027, within a range of $19.02 to $29.06.

Key Takeaways

Protalix BioTherapeutics, Inc. (AMEX:PLX) shares are up 13.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Protalix BioTherapeutics, Inc. trading at a premium to the broader market with a P/E of -28.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.68, suggesting 267.8% upside. Our AI forecast model points to short-term weakness (-15.25% over two weeks), a medium-term fall (-61.86% over three months), and a longer-term gain (824.58% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Protalix BioTherapeutics, Inc. (PLX) stock price?

Protalix BioTherapeutics, Inc. (AMEX: PLX) stock price is $2.31 in the last trading session. During the trading session, PLX stock reached the peak price of $2.39 while $2.28 was the lowest point it dropped to. The percentage change in PLX stock occurred in the recent session was -2.95% while the dollar amount for the price change in PLX stock was - $0.07.

PLX's industry and sector of operation?

The AMEX listed PLX is part of Biotechnology industry that operates in the broader Healthcare sector. Protalix BioTherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PLX?

Ms. Yael Fellous
Vice President of HR
Mr. Yaron Naos
Senior Vice President of Operations
Mr. Dror Bashan
Pres, Chief Executive Officer & Director
Mr. Eyal Rubin M.B.A.
Senior Vice President, Chief Financial Officer, Treasurer & Corporation Sec.

How PLX did perform over past 52-week?

PLX's closing price is 78.79% higher than its 52-week low of $1.32 where as its distance from 52-week high of $3.19 is -26.02%.

How many employees does PLX have?

Number of PLX employees currently stands at 213.

Link for PLX official website?

Official Website of PLX is: https://www.protalix.com

How do I contact PLX?

PLX could be contacted at phone 201 696 9345 and can also be accessed through its website. PLX operates from 2 University Plaza, Hackensack, NJ 07601, United States.

How many shares of PLX are traded daily?

PLX stock volume for the day was 493.3K shares. The average number of PLX shares traded daily for last 3 months was 1.26M.

What is the market cap of PLX currently?

The market value of PLX currently stands at $185.72M with its latest stock price at $2.31 and 80.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	213
Beta	-0.23
Sales or Revenue	$65.49M
5Y Sales Change%	-0.583%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PLX Company Profile and Key Details

Protalix BioTherapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics